Inari Medical price target lowered to $55 from $60 at Truist

Truist lowered the firm’s price target on Inari Medical to $55 from $60 and keeps a Hold rating on the shares. The company’s “modest” Q2 revenue beat and raise was good to see, but the upside may have been shy of the elevated expectations heading into the quarter, the analyst tells investors in a research note. A worse than expected operating profit loss could “strike a nerve” in an environment where SMIDs are getting graded harder on the directionality of their profit trends, the firm added.